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a b s t r a c t 
Gaucher disease (GD) is caused by mutations in the gene GBA1, which encodes for the synthesis of the enzyme 
lysosomal glucocerebrosidase (GCase). Lack or deficiency of GCase activity causes accumulation of glucosylce- 
ramide in the lysosomes of the monocyte-macrophage system in the bone marrow, spleen, and liver, and less 
frequently in the lungs and the central nervous system; this accumulation results in cell damage and organ dys- 
function. 
Currently available diagnostic algorithms are based on the well-recognized hematological manifestations 
(cytopenia and splenomegaly), which are the manifestations most commonly associated with GD. However, 25 
to 32% of patients have been found to present with bone signs and/or symptoms as the only or main presenting 
sign of the disease. 
A number of physicians may be unaware of this clinical presentation of GD, and may therefore delay in 
establishing diagnosis and initiating treatment, when necessary. 
We developed an educational program for early detection and diagnosis of GD, which includes a diagnostic 
algorithm based on GD-related bone manifestations. 
We herein report the case of a girl with bone symptoms as the only first manifestation of GD that were 
mistaken for stress fracture and osteomyelitis, and who was seen by 5 different specialists over a 4-year period 
before she was accurately diagnosed with GD. 
The case presented here shows the usefulness of the educational program for early detection and diagnosis 





































Early treatment is important since it reverses cytopenias and
isceromegalies and though it does not totally prevent onset of bone
esions, it decreases their frecuency. Although bone symptoms are
resent in 25-32% of patients, they are not usually associated with GD.
his lack of awareness may cause delays in the diagnosis and start of
reatment. We aware of the efficacy in developing an educational pro-
ram and propose a diagnostic algorithm based on bone manifestations
uspicious of GD 
ntroduction 
Gaucher disease (GD) is the most frequent lysosomal disease. It is
aused by mutations in the gene GBA1, which encodes for the synthesis
f the enzyme lysosomal glucocerebrosidase (GCase). Lack or deficiency
f GCase activity causes accumulation of glucosylceramide in the lyso-
omes of the monocyte-macrophage system in the bone marrow, spleen,∗ Corresponding author. 
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em, and which results in cell damage and organ dysfunction. 
It is known that GD has a continuous spectrum of severity, but tradi-
ionally three subtypes have been described based on the absence (Type
) or presence of neurological symptoms (Types 2 and 3). 
The most frequent phenotype is type 1 GD (GD1), presenting
ainly with hematologic, visceral, and skeletal manifestations. In-
idence ranges from 1/40,000 to 1/60,000 in the overall pop-
lation, and increases to 1/800 births in the Ashkenazi Jewish
opulation. 
Clinical suspicion of GD1 is traditionally associated with signs asso-
iated with and/or the presence of spleno-hepatomegaly and cytopenia,
hich have a 30 to 50% incidence as first or presenting symptom, and
 60-95% incidence as the leading symptom at the time of diagnosis 2-7 .
iagnostic algorithms for Gaucher disease are therefore based on these
ost frequently presenting signs. Of note, these algorithms are mainly
sed by hematologists 8-10 . il 2020 
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Fig. 1. X-rays showing Erlenmeyer flask deformity in right femur and femoral 







































t  However, 25 to 32% of patients have been found to present with
one signs and/or symptoms as the only or main presenting sign of the
isease 11-12 . The lack of awareness of this fact among physicians who
ave no training in detecting this disease often causes delays in diagno-
is, and hence in the initiation of specific treatment when necessary 6,7 . 
According to the literature, 80% to 95% of patients with GD1, includ-
ng asymptomatic patients, present with some form of bone involvement
t the time of diagnosis. Presenting signs/symptoms may include: Er-
enmeyer flask (EM) deformity, decreased bone mineral density (BMD),
one infarcts (BI), osteosclerosis, avascular bone necrosis (AVN), oste-
lytic lesions, fractures (Fx), bone pain, and bone crises. Between 27
nd 63% of patients report a history of bone pain, and 20% report a
istory of bone crises; this shows that failure to diagnose promptly al-
ows progression of bone involvement. Delayed diagnosis and initiation
f treatment lead to the development of irreversible bone complications
hat affect function, mobility, and quality of life 2,4,13-15 . 
Enzyme replacement therapy (ERT) involving GCase infusions has
een used since 1991, and has been proven to substantially improve
ytopenia and visceromegaly in all patients and growth and peak bone
ass in children, and to diminish the frequency of irreversible bone
omplications 16-18 . Early treatment has also been proven to have a ben-
ficial effect on bone pain and bone crises, on bone mineral density, and
n the degree of bone marrow infiltration. 
In view of the difficulties in timely diagnosis of GD in patients with
one involvement as presenting sign of the disease, we developed an
ducational program and a diagnostic algorithm based on bone mani-
estations suggestive of GD. Since 2017, the program has been promoted
mong health professionals in Argentina through meetings at hospitals,
resentations at congresses, and courses on bone diseases. 
We herein present the case of a girl with bone symptoms as only
anifestation of GD, and who was diagnosed as a result of the imple-
entation of this educational program. 
ASE REPORT 
We present the case of a term-born female patient with normal
rowth and development. In her first year of life she was hospitalized
or gastroenteritis; during hospitalization she was also tested for celiac
isease due to mild anemia and lactose intolerance. 
At age 7 years, she complained of pain on right knee flexion.
oentgenograms showed a radiolucent lesion with sclerotic borders in
he distal metaphysis of the right femur ( Fig. 1 ), which was interpreted
s a stress fracture in the healing phase, and was confirmed by mag-
etic resonance imaging. Retrospective analysis allowed detecting EM
eformity in both femurs, which had previously gone undetected. 
At age 10 years 4 months, severe knee pain recurred in the distal
hird of the right femur, with signs of inflammation, high erythrosedi-
entation rate and serum C-reactive protein, slight anemia, and leuko-
ytosis. She was hospitalized with presumptive diagnosis of septic arthri-
is and osteomyelitis. 
MRI and bone biopsy were consistent with osteomyelitis. In addi-
ion, histopathological examination showed the presence of mononu-
lear leukocytes and a fair quantity of foamy histiocytes staining pos-
tive for CD 68 and negative for CD1 ( BenchMrkGX -Roche) . Although
ultures were negative, IV antibiotic therapy was administered. The pa-
ient’s recovery was satisfactory. 
At age 11 years and 2 months, she suffered an episode of pain in her
eft lower limb. MRI results were consistent with osteomyelitis of the left
istal femoral diaphysis, and myositis in the anterior rectus muscle and
osterior muscles. No pathogenic microorganisms were detected in the
one culture, and the histopathological study showed lymphohistiocytic
nfiltrate and scant macrophages, with no microorganisms or atypical
roliferation. Blood cultures were performed twice, and results were
egative both times. The condition was diagnosed as chronic recurrent
steomyelitis. Following consultation with a specialist in rheumatology who had
articipated in one of the GD educational talks, her attending physi-
ians saw the need to consider GD1. For this purpose, a dry blood spot
ample was collected on filter paper and sent for determination of GCase
ctivity. The results showed enzymatic deficiency, and diagnosis of GD1
as confirmed through the use of an enzyme assay test to measure gluco-
erebrosidase enzyme activity in circulating leukocytes. Genetic analysis
howed the patient’s GBA1 gene genotype was c.1226A > G /RecNcil. 
Following diagnosis of GD1, complete bone assessment was per-
ormed. Simple radiographs of both femurs showed EM deformity and
clerotic lesions consistent with bone infarcts in the central and distal
iaphyseal regions ( Fig. 2 A), which were confirmed by MRI ( Fig. 2 B).
one mineral density of the lumbar spine and total skeleton was nor-
al (Z-score -0.9 and -1.1 respectively). Blood tests showed high levels
f serum chitotriosidase (1566 um/l/h; reference range = 7.7-110) and
erritin (224 ng/ml; reference range = 4.6 – 204), two known markers of
D1 activity. Biochemical parameters of bone and mineral metabolism
ere normal, and bone remodeling marker levels were normal accord-
ng to age. 
Although no visceromegaly was palpable on physical examina-
ion, MRI showed the spleen was 3.2-fold larger than the theoretical
ormal value for the patient’s weight and was consistent with mild
plenomegaly, and liver volume was 1.16-fold higher than the nor-
al theoretical volume for the patient’s weight; platelet count was
44x10 9 /L and hemoglobin levels were 11g/L . ERT with velaglucerase
as initiated. 
ISCUSSION 
The presenting clinical manifestations of GD in the patient shown
ere were unclear, since the fracture and episodes of bone pain were not
ccompanied by cytopenia or visceromegaly, which are the more widely
ecognized features of the disease. This would explain why the patient
as seen by 5 different specialists (a pediatrician, a traumatologist, an
nfectologist, an oncologist, and a rheumatologist) over a 4-year period,
efore she was accurately diagnosed with GD. 
Given that the presence of bone symptoms as initial manifestation
f GD is less known, delay in diagnosis in patients with no hematologic
lterations or visceromegaly is not infrequent. 
According to a retrospective review of the clinical records of 44 pa-
ients with documented onset of GD at or before the age of 16 years,
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Fig. 2. 2A - X-ray of both femurs showing scle- 
rotic images with ill-defined borders, compati- 
ble with sequelae of a bone infarct. 
2B. Coronal MRI view of both femurs evidenc- 
ing changes in signal intensity in the central 
and distal thirds, compatible with bone infarcts 


























































































one involvement (AVN, BI, bone pain, and misdiagnosis of osteomyeli-
is) was the second most common clinical presentation, accounting for
2.4% of cases 11 . 
A more detailed analysis of the history of our patient allows positing
hat the first fracture at age 7 years may have occurred as a consequence
f bone weakening due to infiltration by Gaucher cells. The typical ra-
iographic appearance of EM deformity, which corresponds with the
xpansion of the bone marrow and subsequent alteration of bone re-
odeling caused by infiltration of Gaucher cells 14 , went undetected at
he time. 
The ensuing episodes of severe pain in both distal femurs at age 10
nd 11 years attributed to osteomyelitis could be interpreted as bone
rises, which are characterized by episodes of acute pain that begins as
 dull pain that intensifies and becomes severe after 2 to 3 days, and
hat can persist for 7 to 10 days 15 . It generally occurs together with
igns of local inflammation, leukocytosis, and elevated erythrosedimen-
ation, and can present with or without fever, which explains why it is
asily confused with osteomyelitis 19,20 . However, toxemia is absent and
ultures are negative during a GD-related bone crisis, as occurred with
he patient described here. A bone scintigraphy can contribute data for
ifferential diagnosis between osteomyelitis and bone crisis, since in-
reased uptake is observed in osteomyelitis and decreased uptake is ob-
erved in acute bone crisis. Nevertheless, severe cases of osteomyelitis
an also show a photopenic area (cold osteomyelitis), which is impos-
ible to distinguish from a bone crisis 21 . During an acute bone crisis,
RI shows localized edema in the bone marrow and soft tissues, with
ncreased signal intensity in T2 weighted images, suggestive of hemor-
hage of bone 22 . Retrospective analysis of the patient’s clinical record
nd imaging studies performed prior to diagnosis, in addition to the con-
istently negative bone cultures and the presence of foamy histiocytes
bserved in the first bone biopsy, allowed identifying signs that could
ave been a warning signal of the possible presence of GD. 
The patient met two criteria proposed in the diagnostic algorithm
ased on bone manifestations included in our educational program, i.e.
steomyelitis and bone crises. 
This observation led to the diagnostic suspicion of GD, and prompted
ubmission of samples for assessment of GCase activity. 
It is our understanding that the case presented here shows the use-
ulness of the educational program for early detection and diagnosis of
D that we have been implementing since 2017. 
The educational program mainly targets health professionals who
re consulted about a bone disorder: orthopedists, rheumatologists, ra-
iologists, endocrinologists, general practitioners, and pediatricians. 
The importance of timely diagnosis of GD in patients presenting bone
ymptoms lies in the possibility of initiating early treatment that would
void the irreversible and incapacitating skeletal complications that fre-
uently develop in these patients throughout the natural course of theisease. C  
o  
t
To conclude, GD is an infrequent disease that is recognized mainly
ue to its hematologic alterations. Nevertheless, isolated bone symptoms
ay be the first clinical manifestation, which makes diagnosis difficult.
The case presented here shows the usefulness of an educational pro-
ram and diagnostic algorithm based on bone symptoms for diagnosis
f GD. 
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